Companies › BioInvent International
4 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BI-1910 unclear - mechanism not stated in registry | – | Phase 1 | Solid Tumors | Jul 2027 |
| BI-1607 FAP inhibitor (fibroblast activation protein inhibitor) | FAP | Phase 1 | Melanoma Metastatic | Jul 2027 |
| BI-1206 anti-CD32B monoclonal antibody | FCGR2B | Phase 1 | Indolent B-Cell Non-Hodgkin Lymphoma; Solid Tumor, Adult | Sep 2027 |
| BI-1808 TNFRSF14 (HVEM) agonist | – | Phase 1 | Advanced Malignancies | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06205706 | BI-1910 | Phase 1 | Solid Tumors | Oncology | Jul 2027 |
| NCT06784648 | BI-1607 | Phase 1 | Melanoma Metastatic | Oncology | Jul 2027 |
| NCT03571568 | BI-1206 | Phase 1 | Indolent B-Cell Non-Hodgkin Lymphoma | Oncology | Sep 2027 |
| NCT04219254 | BI-1206 | Phase 1 | Solid Tumor, Adult | Oncology | Nov 2027 |
| NCT04752826 | BI-1808 | Phase 1 | Advanced Malignancies | Oncology | Jan 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.